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Background: The purpose of this study was to estimate the effects of a 3-year dietary intervention on age-related
changes in triglyceride and apolipoprotein (apo A-V) levels in patients with impaired fasting glucose (IFG) or
new-onset type 2 diabetes as a function of the APOA5 -1131 T > C polymorphism.
Methods: We genotyped the APOA5 -1131 T > C polymorphism in 203 Korean individuals with IFG or new-onset
type 2 diabetes for the TT (n = 91), TC (n = 98), and CC (n = 14) alleles. Plasma apo A-V and triglyceride levels were
evaluated at baseline and after a 3-year dietary intervention.
Results: Our results showed that HDL, glucose, insulin, HOMA-IR index, free fatty acids, and apo A-V decreased and
brachial-ankle pulse wave velocity (ba-PWV) and malondialdehyde (MDA) increased at the 3-year follow-up visit
compared with baseline. Plasma apo A-V levels were reduced in subjects with the C allele (TC or CC) (P = 0.036) and
triglyceride levels were reduced in subjects with the TT allele (P = 0.047). Subjects with the C allele showed lower
post-treatment apo A-V and higher post-treatment fasting triglyceride levels than subjects with the TT allele.
Changes in apo A-V and triglyceride levels were negatively correlated in subjects with the TT allele and positively
correlated in subjects with the C allele.
Conclusions: This study showed that the dietary intervention prevented an age-related increase in triglyceride
levels in individuals with IFG or new-onset type 2 diabetes who possess the TT allele, but not the CT or CC allele, of
the APOA5 -1131 T > C polymorphism.
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Apolipoprotein A-V (apo A-V), which was discovered in
2001, is part of the apolipoprotein family (APOA1/C3/
A4). Apo A-V is encoded by the APOA5 gene, which is
located on human chromosome 11q23 and contains three
introns and four exons [1-3]. Although apo A-V is mainly* Correspondence: jhleeb@yonsei.ac.kr
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structure [2], apo A-V also exists in small amounts in
the plasma and plays an important role in the regulation
of triglyceride levels in both human and animal models.
Pennacchio et al. found that triglyceride levels decreased
approximately 66% in transgenic mice that overexpressed
APOA5 and were four times higher in APOA5 knockout
mice compared with control mice [1,3,4].
Elevated triglyceride levels are associated with abnormal
lipid metabolism in patients with type 2 diabetes [1,5].
However, the mechanism underlying the modulation of
triglyceride levels by plasma apo A-V as well as the effect of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[4,6]. Many studies have shown that genetic variations in
the APOA5 gene are associated with hypertriglyceridemia
and coronary heart disease [1,2,7]. However, few studies
have explored genetic variations in the APOA5 gene
in individuals with type 2 diabetes. Therefore, we tested
the effects of a 3-year dietary intervention on triglyceride
and apo A-V levels in patients with impaired fasting
glucose (IFG) or new-onset type 2 diabetes as a function
of their APOA5 polymorphisms.
The -1131 T >C single-nucleotide polymorphism (SNP)
of the APOA5 gene has a significant impact on diseases
[5-7]. A previous study has shown that among healthy,
non-obese Korean men who were genotyped with the TT,
TC, or CC allele of the APOA5 -1131 T >C polymorphism,
triglyceride levels were higher in carriers of the C allele
(TC or CC) compared with carriers of the TT allele. The
levels of small dense low-density lipoprotein (LDL)
cholesterol, high-sensitivity C-reactive protein, and lympho-
cyte DNA damage were also higher in carriers of the C
allele compared with carriers of the TT allele. Therefore,
the C allele of the APOA5 -1131 T >C polymorphism is
significantly associated with risk factors for cardiovascular
disease (CVD) [6]. Furthermore, Xu et al. performed a
meta-analysis of the APOA5 -1131 T >C polymorphism
among East Asian, European, and other ethnic populations
and found that the C allele was associated with
higher levels of fasting triglycerides, total cholesterol,
and LDL cholesterol, and lower levels of high-density
lipoprotein (HDL) cholesterol, especially in East Asian
populations, in which metabolic syndrome was also
increased by approximately 40% [8]. The C allele is more
prevalent in Chinese (26-40%) than in Caucasian (8%)
individuals [7]. Chandak et al. also found a higher
prevalence of the C allele among Indians compared
with Caucasians from the United Kingdom (20% vs. 4%,
respectively; P < 0.001) [9]. Therefore, the C allele and
disease-linked variants are common among the Asian
population.
Carbohydrate-derived calories account for 65% of total
caloric intake and refined rice is the primary source of
carbohydrates among middle-aged adults, according the
2010 Korean National Health and Nutrition Examination
Survey (KNHANES V-1). A high carbohydrate intake
combined with a high prevalence of the APOA5 -1131C
allele may contribute to the relatively high mean serum
triglyceride concentration (142 mg/dL) in the Korean
population (KNHANES V-1). Previous observational
studies and intervention trials have shown that the
APOA5 -1131 T > C polymorphism interacts with dietary
factors, especially dietary fat, to determine triglycer-
ide concentrations [10-14]. Lin et al. recently showed
that elevated triglyceride levels were induced by a
high carbohydrate diet in healthy individuals with theAPOA5 -1131C allele [15]. A clear association exists
between diabetic dyslipidemia and the APOA5 -1131 T > C
polymorphism [16]. Furthermore, there is evidence that a
high-legume, low glycemic index diet reduces fasting
triglyceride levels in insulin-resistant subjects [17].
Therefore, we hypothesized that a 3-year dietary interven-
tion with whole grains and legumes in a high-carbohydrate
diet may mask the adverse effects of a high-carbohydrate
intake among individuals with the C allele of the
APOA5 -1131 T > C polymorphism. Therefore, we studied
the effects of a 3-year high-carbohydrate diet with whole
grains and legumes on circulating levels of apo A-V
and triglycerides in patients with IFG or new-onset
type 2 diabetes as a function of the APOA5 -1131 T > C
polymorphism.
Methods
Study design and participants
Study subjects were recruited from the Health Service
Center (HSC) during routine check-ups at the National
Health Insurance Corporation Ilsan Hospital in Goyang,
Korea between August 2006 and February 2008. Subjects
were sedentary and had not participated in weight-
reduction programs within the previous 3 years. Based
on the data screened from the HSC, subjects with IFG
(fasting glucose between 100 and 126 mg/dL) or new-onset
type 2 diabetes (fasting glucose ≥126 mg/dL) were referred
to the Department of Family Medicine or Internal
Medicine. Their health and lipid profiles were re-screened,
and subjects who satisfied the study criteria were recom-
mended to participate in the dietary intervention program.
Exclusion criteria included a current and/or past history
of CVD, including angina, cancer, abnormal liver or renal
function, thyroid or pituitary disease, and use of any
medications (including anti-hypertensive, lipid lowering,
anti-platelets, and anti-diabetic drugs). The purpose of the
study was carefully explained to all potential subjects and
their written consent was obtained prior to their participa-
tion. During the recruiting period, total 244 subjects were
enrolled (TT: 109, TC: 118, CC: 17). Approximately 83%
of subjects achieved, and finally, a total of 203 subjects
completed the study. The study protocol was approved by
the Institutional Review Board of Yonsei University and
performed in accordance with the Declaration of Helsinki.
Dietary intervention and assessment of dietary
intake/physical activity level
Enrolled subjects visited the center one week before
starting the intervention. Each subject’s habitual diet was
obtained using both a 24-h recall method and a previously
validated semi-quantitative food frequency questionnaire
(SQFFQ) [18]. Analyses were conducted using the data
from the 24-hour recall methods, and the SQFFQ was used
to validate this data. All of the subjects were advised to
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to complete a 3-day food record (2 weekdays and 1 week-
end day) as a baseline measurement. On the 3-day food
record, subjects were instructed to weigh and record the
amount of food before ingestion and any remaining food
after ingestion. This 3-day record was compared with
the 24-hour recall method to verify the habitual diet.
The dietary intervention program started one week
after baseline measurements. The intervention program
replaced each subject’s refined rice intake with equal
parts of legumes, barley, and other whole grains three
times per day as high-carbohydrate sources and increased
their vegetable intake to at least 6 units (30–70 g/unit) per
day to ensure a sufficient dietary fiber intake. To evaluate
and reinforce compliance during the intervention period,
dietitians interviewed the subjects bimonthly via telephone.
Subjects were asked to report their 3-day food records at
each visit. Subjects were also instructed to record
their 24-hour physical activity in a diary every 4 weeks.
Dietary energy values and nutrient content from the 3-day
food records were calculated using the Computer-Aided
Nutritional analysis program (CAN-pro 3.0, Korean
Nutrition Society, Seoul, Korea). Total energy expenditure
(kcal/day) was calculated from the 24-hour physical
activity patterns [19], basal metabolic rate, and the
specific dynamic actions of the food intake. Basal
metabolic rate was calculated for each subject with
the Harris–Benedict equation [20].
Anthropometric parameters and blood collection
Body weight and height were measured to calculate body
mass index (BMI, kg/m2). Waist circumference was
measured at the umbilical level with the subject in the
standing position after normal expiration and hip girth
was measured at the widest part of the hip to calculate
the waist to hip ratio (WHR). Blood pressure (BP) was
measured in the left arm of seated patients with an
automatic BP monitor (TM-2654, A&D, Tokyo, Japan)
after 20 minutes of rest. Venous blood specimens were
collected after a 12-hour fasting period in EDTA-treated
and plain tubes that were centrifuged to produce either
plasma or serum and stored at −70°C.
Serum lipid profile, free fatty acids, fasting glucose,
insulin concentration, and insulin resistance
Fasting serum concentrations of total cholesterol, triglycer-
ides, and free fatty acids were measured using the Hitachi
7150 Autoanalyzer (Hitachi Ltd., Tokyo, Japan). Blood was
precipitated using apoB-containing lipoproteins with
dextran sulfate magnesium. Inter and intra-assay precision
of total cholesterol was 1.73% and 1.52%, triglyceride was
2.52% and 1.28%, and free fatty acid was 3.73% and 0.99%,
respectively. HDL concentrations in the supernatants were
measured enzymatically. Inter and intra-assay precisionwas 1.61% and 1.37%. LDL was indirectly estimated in
subjects with serum triglyceride concentrations less than
400 mg/dL using the Friedewald formula: LDL = total
cholesterol - [HDL + (triglycerides/5)]. In subjects with
serum triacylglycerol concentrations more than 400 mg/mL,
LDL was measured directly using an enzymatic method
on a Hitachi 7150 Autoanalyzer (Hitachi Ltd, Tokyo,
Japan). Fasting glucose concentrations were measured
with a glucose oxidase method from the Beckman Glucose
Analyzer (Beckman Instruments, Irvine, CA). Inter and
intra-assay precision was 1.14% and 0.94%. Insulin concen-
trations were measured by radioimmunoassay from the
Immuno Nucleo Corporation (Stillwater, MN). Inter and
intra-assay precision was 2.1% and 6.5%. The homeostasis
model assessment of insulin resistance (HOMA-IR) was
calculated using the following formula: HOMA-IR = [fast-
ing insulin (μIU/mL) × fasting glucose (mmol/L)] × 22.5.
Serum high-sensitivity C-reactive protein, plasma
malondialdehyde, LDL particle size, and brachial-ankle
pulse wave velocity
Serum high-sensitivity C-reactive protein (hs-CRP) con-
centrations were measured by the Express Plus™ auto-
analyzer (Chiron Diagnostics Co., Walpole, MA, USA) and
high-sensitivity CRP-Latex(II) X2 kit (Seiken Laboratories
Ltd., Tokyo, Japan). Inter and intra-assay precision was
2.08% and 2.46%. Malondialdehyde (MDA) was measured
by the TBARS Assay kit with thiobarbituric acid-reactive
substances (Zepto-Metrix Co., Buffalo, NY, USA). Inter
and intra-assay precision was 1.9% and 1.0%. Particle size
distribution of LDL isolated by sequential flotation ultra-
centrifugation was examined by a pore gradient lipoprotein
system (CBS Scientific, CA, USA) on commercially avail-
able, non-denaturing polyacrylamide slab gels containing a
linear gradient of 2-16% acrylamide (Alamo Gels Inc., San
Antonio, TX, USA). Standards of latex beads (34 nm)
thyroglobulin (17 nm), apoferritin (12.2 nm), and catalase
(10.4 nm) were used to estimate the relative migration
rates of each band. Gels were scanned using a GS-800 Cali-
brated Imaging Densitometer (Bio-Rad, Graz, Austria). In-
ter and intra-assay precision was 2.29% and 3.88%.
Brachial-ankle pulse wave velocity (ba-PWV) was mea-
sured by the automatic waveform analyzer (model VP-
1000; Nippon Colin Ltd., Komaki, Japan). Subjects were ex-
amined in the supine position after 5 minutes of rest.
Plasma apolipoprotein A-V and APOA5 -1131 T > C
genotyping
Plasma apo A-V was measured by enzyme immunoassay
(Human Apolipoprotein A ELISA kit, Millipore, MO). The
results were read at 450 nm by the Victor2 (Perkin Elmer
Life Sciences, Turka, Finland). Inter and intra-assay
precision was 2.46% and 7.45%. Genomic DNA was
extracted from 5 mL of whole blood using a commercially
Table 1 Effects of a 3-year dietary intervention on
anthropometric and biochemical markers
Pre-treatment Post-treatment P-value
Male/female (%) 58.6/41.4
Age (year) 48.2±0.64 51.3±0.64 <0.001
Weight (kg) 66.6±0.72 66.3±0.71 0.210
Body mass index (kg/m2) 24.6±0.21 24.5±0.20 0.285
Systolic BP (mmHg) 121.1±0.97 122.4±0.96 0.158
Diastolic BP (mmHg) 74.9±0.72 75.8±0.75 0.171
Total cholesterol (mg/dL)∮ 194.8±2.29 198.0±2.87 0.362
LDL cholesterol (mg/dL)∮ 117.9±2.20 123.2±2.73 0.110
HDL cholesterol (mg/dL)∮ 52.7±0.98 50.3±1.02 0.002
Triglycerides (mg/dL)∮ 122.8±4.93 127.6±5.82 0.714
Glucose (mg/dL)∮ 109.8±0.67 108.3±1.28 0.004
Insulin (μIU/mL)∮ 9.04±0.26 8.27±0.27 <0.001
1HOMA-IR∮ 2.47±0.08 2.24±0.09 <0.001
2hs-CRP (mg/dL)∮ 1.24±0.12 1.31±0.27 0.451




3ba-PWV (cm/sec)∮ 2694.2±28.7 2758.3±31.1 0.002




Estimates of daily nutrient
intake
Energy intake (kcal) 2196.3±22.3 2162.7±20.3 0.009
Carbohydrate (%) 61.7±0.10 57.5±0.07 <0.001
Protein (%) 16.9±0.08 17.5±0.06 <0.001
Fat (%) 21.7±0.11 22.9±0.09 <0.001
Crude fiber (g)∮ 11.3±0.43 15.0±0.56 <0.001
5PUFA/SFA∮ 1.73±0.07 2.08±0.08 0.003
Mean ± SE, n = 203. ∮Log-transformed, P-values derived from paired t-test.
1HOMA-IR = {fasting insulin (μIU/mL) × fasting glucose (mmol/L)}/22.5.
2hs-CRP = high sensitivity C-reactive protein. 3ba-PWV = brachial-ankle pulse
wave velocity. 4MDA =malondialdehyde. 5PUFA/SFA = ratio of polyunsaturated
to saturated fatty acids.
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purification kit, Promega Corp., Madison, WI, USA)
according to the manufacturer’s instructions. Genotyping
was performed by SNP-ITTM assays using single primer
extension technology (SNPstream 25KTM System, Orchid
BioSciences, NJ, USA). The colorimetric reactions
were detected by an enzyme-linked immunosorbent
assay (ELISA) reader, and the genotype was determined
with QCReview™ software using methods that have been
described previously [21].
Statistical analysis
Statistical analyses were performed using SPSS version 12.0
for Windows (Statistical Package for the Social Sciences,
SPSS Inc., Chicago, IL). The Hardy-Weinberg Equilibrium
(HWE) analysis was performed using Haploview version
3.32 (http://www.broadinstitute.org/scientific-community/
science/programs/medical-and-population-genetics/haplo-
view/haploview). Prior to statistical analysis, each variable
was tested for normality. Logarithmic transformations were
performed on skewed variables. However, for graphical
and interpretation purposes, values are reported as the
untransformed variables. The effects of the dietary inter-
vention were evaluated using a paired t-test. The genotype
effects were tested by either a one-way analysis of variance
(ANOVA) with a Bonferroni correction for multiple
comparisons or an independent t-test. The association
between changes in apo A-V concentrations and other
metabolic variables was computed with Pearson and
partial correlation coefficients. A general linear model
(GLM) analysis was performed to compare confounding
factors. Multiple regressions were performed to determine
the independent predictors of apo A-V changes. The results
are reported as the mean ± SE. P < 0.05 was considered
statistically significant.
Results
Distribution of the APOA5 -1131 T > C polymorphism
Among 203 Korean patients with IFG or new-onset type
2 diabetes, 91 were homozygous (TT) for the T allele, 98
were heterozygous for the C allele (TC), and 14 were
homozygous (CC) for the C allele of the APOA5 -1131 T >
C polymorphism. These frequencies did not deviate
significantly from the Hardy-Weinberg equilibrium.
The frequency of the C allele was 0.310, which is
slightly higher than the frequency that was previously
reported among a healthy Korean population (0.285)
[22]. To increase statistical power, we pooled carriers
of the less common allele (TC and CC).
Clinical characteristics and nutrient intake before and
after a 3-year dietary intervention
At the 3-year follow-up visit, fasting HDL, glucose, insulin,
HOMA-IR, free fatty acids, and apo A-V had decreased,and MDA and ba-PWV had increased from baseline
across all subjects (Table 1). There were significant
increases from baseline in both fiber intake and the
ratio of polyunsaturated to saturated fatty acids as
well as a slight decrease in total energy expenditure
and total energy intake. The mean BMI of the subjects did
not change, and no significant change was observed in
other biochemical markers (Table 1).
Effects of a 3-year dietary intervention as a function of
the APOA5 -1131 T > C genotype
There were no significant differences in the distribution
of sex, age, BMI, WHR, BP, total cholesterol, LDL, hs-
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APOA5 -1131 T > C genotypes at baseline or the 3-year
follow-up visit (data not shown). The mean (±SEs) fasting
apo A-V and triglyceride levels at baseline and the 3-year
follow-up visit across the APOA5 -1131 T > C genotypes
are shown in Figure 1. At baseline, there was a significant
association between apo A-V levels and the -1131 T >C
genotype (P = 0.009) such that apo A-V levels were
approximately 10% and 38% lower in TC and CC allele
carriers, respectively, compared with TT allele carriers.
Triglyceride levels were also approximately 17% and
34% higher in TC and CC allele carriers, respectively,
compared with TT allele carriers at baseline. At the
3-year follow-up visit, plasma apo A-V levels were re-
duced in C allele carriers (P = 0.036) and fasting triglycer-
ide levels were reduced in TT allele carriers (P = 0.047)
(Table 2). After adjusting for baseline levels, significant
associations were found between apo A-V changes and the
APOA5 genotype (TT: −7.77 ± 10.79 ng/mL; TC: −23.99 ±
10.52; CC: −16.71 ± 16.11; P = 0.012) and between tri-
glyceride changes and the APOA5 genotype (TT: −7.88 ±
5.44 mg/dL; TC: 14.38 ± 6.21; CC: 19.57 ± 18.58; P = 0.004)
(Figure 1). TC or CC allele carriers had significantly lower
post-treatment apo A-V levels and higher post-treatment
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P2 = 0.012 
‡
†
Figure 1 Fasting apolipoprotein A-V and triglyceride levels at baselin
and mean changes as a function of the APOA5 -1131 T > C genotyp
§Log-transformed. P1, unadjusted P value; P2, baseline-adjusted P value. *P <
t-test. †P < 0.05 compared with the TT allele; ‡P < 0.05 compared with the T
TC allele tested by a one-way ANOVA with a Bonferroni correction.The mean (±SEs) fasting HDL, glucose, insulin, HOMA-
IR index, free fatty acids, LDL particle size, MDA, and
ba-PWV values at both baseline and the 3-year follow-
up visit are reported in Table 2 as a function of the
APOA5 -1131 T > C genotype. At baseline, C allele car-
riers had lower HDL levels (P = 0.024) than TT allele
carriers. At the 3-year follow-up visit, fasting glucose
(P < 0.001), insulin (P < 0.001), the HOMA-IR index
(P < 0.001), and free fatty acids (P = 0.020) were reduced in
TT allele carriers but not C allele carriers. C allele carriers
had decreased HDL levels (P = 0.005) and LDL particle
size (P = 0.048) and increased MDA (P < 0.001) and ba-
PWV (P < 0.001) at the 3-year follow-up visit com-
pared with baseline.
TT allele carriers had a greater reduction in glucose
(P = 0.030) and the HOMA-IR index (P = 0.047) than
C allele carriers after adjusting for baseline levels. C
allele carriers had a greater reduction in LDL particle
size (P = 0.006) and a greater increase in plasma
MDA (P = 0.048) and ba-PWV (P = 0.046) than TT
allele carriers after adjusting for baseline levels. C
allele carriers also had lower post-treatment HDL
levels (P = 0.001), smaller post-treatment LDL particle sizes
(P = 0.008), and higher post-treatment MDA (P = 0.020)





















TT                  TC                  CC
P1 = 0.020
P2 = 0.004 
e (white square) and the 3-year follow-up visit (gray square)
e. Data (mean ± SE) included 91 (TT), 98 (TC), and 14 (CC) subjects.
0.05 compared with baseline values for each genotype by paired
T allele after adjusting for baseline values; #P < 0.05 compared with the
Table 2 Effects of a 3-year dietary intervention on apolipoprotein A-V, triglycerides, HDL, glucose, insulin, HOMA-IR, LDL
particle size, MDA, and ba-PWV at baseline and the 3-year follow-up visit as a function of the APOA5 -1131 T > C genotype
APOA5 -1131 T > C P-
value
Pa-
valueTT (n = 91) TC and CC (n = 112)
Apolipoprotein A-V (ng/mL)
Before∮ 217.8±10.6 188.6±10.2 0.011
After∮ 210.0±10.8 166.4±8.32* 0.001
Change −7.77±10.8 −23.0±9.35 0.285 0.004
Triglycerides (mg/dL)
Before∮ 110.9±6.20 132.5±7.28 0.022
After∮ 103.0±6.88* 147.6±8.51 <0.001
Change −7.88±5.44 15.0±5.88 0.005 0.001
HDL cholesterol (mg/dL)
Before∮ 55.1±1.53 50.8±1.26 0.024
After∮ 53.5±1.46 47.7±1.39** 0.001
Change −1.62±1.15 −3.11±1.18 0.372 0.051
Glucose (mg/dL)
Before∮ 109.7±1.00 109.9±0.90 0.874
After∮ 105.7±1.10*** 110.4±2.11 0.064
Change −4.07±0.98 0.46±1.68 0.030 0.030
Insulin (μIU/mL)
Before∮ 9.19±0.36 8.93±0.37 0.425
After∮ 7.96±0.36*** 8.52±0.39 0.375
Change −1.23±0.38 −0.41±0.35 0.115 0.173
1HOMA-IR
Before∮ 2.51±0.11 2.44±0.11 0.469
After∮ 2.10±0.10*** 2.36±0.13 0.177
Change −0.39±0.11 −0.07±0.10 0.034 0.047
Free fatty acids (μEq/L)
Before∮ 540.8±22.8 523.7±20.3 0.577
After∮ 494.2±24.1* 502.4±22.0 0.836
Change −46.6±25.6 −21.3±24.9 0.481 0.620
LDL particle size (nm)
Before∮ 23.7±0.10 23.7±0.08 0.648
After∮ 23.8±0.11 23.4±0.09* 0.008
Change 0.10±0.09 −0.23±0.09 0.014 0.006
2MDA (nmol/mL)
Before∮ 10.1±0.31 10.5±0.29 0.418
After∮ 10.7±0.42 11.9±0.35*** 0.020
Change 0.48±0.39 1.38±0.32 0.078 0.048
3ba-PWV (cm/sec)
Before∮ 2678.0±36.4 2707.3±42.9 0.736
After∮ 2701.4±38.9 2804.6±46.4*** 0.134
Change 23.4±29.7 97.3±25.3 0.058 0.046
Mean ± S.E.∮Log-transformed, *P< 0.05, **P< 0.01, ***P< 0.001 compared with baseline values for each genotype tested by paired t-test. P-values derived from independent
t-test. Pa-values derived from independent t-test after adjusting for baseline values. 1HOMA-IR = {fasting insulin (μIU/mL) × fasting glucose (mmol/L)}/22.5.
2MDA =malondialdehyde. 3ba-PWV = brachial-ankle pulse wave velocity.
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and metabolic parameters
Correlations between the changes in apo A-V levels and
metabolic parameters were determined after adjusting
for age, sex, and changes in body weight (r1), initial
triglyceride levels (r2), and initial apo A-V levels (r3)
(Table 3). Across all subjects, changes in apo A-V levels
were negatively correlated with baseline apo A-V levels
(r1 = −0.543, r2 = −0.555, all P < 0.001). In TT allele
carriers, changes in apo A-V levels were negatively
correlated with baseline apo A-V levels (r1 = −0.535,
r2 = −0.552, all p < 0.001) and changes in triglyceride
levels (r3 = −0.299, p3 = 0.006). In C allele carriers,
changes in apo A-V levels were negatively correlated
with baseline apo A-V levels (r1 = −0.613, r2 = −0.617,
all of P < 0.001), but positively correlated with changes
in triglyceride levels (r1 = 0.207, p1 = 0.038; r2 = 0.221,
p2 = 0.028).
Independent predictors of apo A-V and triglyceride
changes
Based on these results, we performed a multiple regression
to determine independent predictors of apo A-V changes
(Table 4). The APOA5 -1131 T > C genotype, age, baseline
BMI, baseline apo A-V levels, baseline triglyceride
levels, change in triglyceride levels, baseline HDL,
change in HDL, baseline glucose, change in glucose,
baseline HOMA-IR, change in HOMA-IR, baseline
free fatty acids, and change in free fatty acids were
tested. The APOA5 -1131 T > C genotype emerged as an
independent predictor of changes in apo A-V levels
(β = −24.532 ± 11.686, P = 0.037) along with baseline
apo A-V levels (β = −107.870 ± 12.445, P < 0.001) across
all subjects. Baseline apo A-V levels and changes in
triglyceride levels and changes in HDL cholesterol levels
also emerged as independent predictors of changes in apo
A-V levels (β = −112.767 ± 19.550, P < 0.001; β = −0.404 ±
0.191, P = 0.038; β = 3.280 ± 1.007, P = 0.002, respectively)
in both TT and C allele carriers (β = −101.958 ± 16.096;
P < 0.001, β = 0.349 ± 0.133, P = 0.010; β = 2.239 ± 0.666,
P = 0.001, respectively). To figure out the independent
predictors of triglyceride changes, APOA5 -1131 T > C
genotype, age, baseline BMI, baseline apo A-V levels,
baseline triglyceride levels, change in triglyceride levels,
change in HDL, baseline glucose, change in glucose,
baseline HOMA-IR, and change in HOMA-IR were tested
(data not shown). The APOA5 -1131 T > C genotype
emerged as an independent predictor of changes in
triglyceride levels (β = 17.668 ± 8.200, P = 0.033) along
with baseline triglyceride levels (β = −35.455 ± 8.401,
P < 0.001) and baseline apo A-V levels (β = −20.856 ±
10.025, P = 0.039) across all subjects. Baseline triglyceride
levels and changes in apo A-V levels also emerged as
independent predictors of changes in triglyceride levels(β = −36.641 ± 11.743, P = 0.003 and β = −0.179 ± 0.068,
P = 0.010, respectively) in both TT and C allele carriers
(β = −29.611 ± 12.206, P = 0.017 and β = 0.182 ± 0.078,
P = 0.001, respectively). However, baseline apo A-V
levels had shown as predictors of changes in triglyceride
levels only in TT allele (β = −31.465 ± 13.668, P = 0.024).
Discussion
This study shows an effect of the APOA5 -1131 T > C
polymorphism in patients with IFG or type 2 diabetes
among the Korean population. The frequencies of the
APOA5 -1131 T > C alleles (TT: 44.8%, TC: 48.3%, CC:
6.9%) did not deviate from the Hardy-Weinberg equilib-
rium. Our data showed that the TT allele is associated with
lower triglyceride levels compared with the C allele, which
agrees with a study by Xu et al. that demonstrated higher
levels of fasting triglycerides, total cholesterol, LDL, and
HDL, as well as a 33% increased risk of metabolic
syndrome, in 51,868 Chinese subjects with the C allele [8].
In our previous research, CC allele carriers showed lower
apo A-V levels than TT allele carriers, and showed associ-
ation with greater triglyceride levels, smaller LDL particle
size, and lower HDL-cholesterol [23]. Similarly, Li et al.
found a higher C allele frequency among individuals with
high total cholesterol compared with individuals with
normal total cholesterol levels in both ethnic populations
(Hei Yi Zhuang and Han Chinese; P < 0.05) [24]. However,
a 15-year follow-up study of healthy men in the United
Kingdom (the Northwick Park Heart Study II) showed no
effects of the APOA5 -1131 T >C polymorphism on the
risk of type 2 diabetes [25]. This discordance across studies
may be related to the differences among ethnic groups.
The C allele of the APOA5 -1131 T >C is more common
among Asian populations (34% frequency in Japanese,
28-30% in Koreans, and 7.4% in Caucasians) [26,27].
The living conditions and progression of the disease
as well as other subject characteristics may also affect
the results.
The number of people diagnosed with diabetes worldwide
is approximately 171 million, with a predicted increase to
366 million people by 2030 [28]. Elevated triglyceride
levels as well as changes in plasma lipoproteins are
associated with diabetes [24]. In the Framingham
Heart Study, high VLDL levels which prompted the
consideration of high triglyceride levels were associ-
ated with the development of diabetes, especially
among subjects who were obese [29]. The relationship
between obesity and diabetes is interdependent. Therefore,
diet and exercise are extremely important for patients
with diabetes.
Whole grain and legume consumption is known to
decrease insulin resistance or insulin demand and improve
lipid profiles, including decreasing triglyceride levels [30].
In particular, soy intake has been associated with increased
Table 3 Relationship between changes in plasma apolipoprotein A-V levels and metabolic parameters
Changed apo A-V levels
All subjects TT allele C allele (TC and CC)
r1 p1 r2 p2 r3 p3 r1 p1 r2 p2 r3 p3 r1 p1 r2 p2 r3 p3
Baseline levels
Triglyceride∮ −0.018 0.809 - - - - −0.082 0.456 - - - - 0.052 0.608 - - - -
Apo A-V∮ −0.543 <0.001 −0.555 <0.001 - - −0.535 <0.001 −0.552 <0.001 - - −0.613 <0.001 −0.617 <0.001 - -
Free fatty acids∮ −0.159 0.030 −0.158 0.031 −0.047 0.529 −0.086 0.439 −0.066 0.554 −0.050 0.656 −0.237 0.017 −0.233 0.020 −0.036 0.722
HDL cholesterol∮ −0.203 0.005 −0.221 0.002 −0.105 0.153 −0.156 0.156 −0.173 0.118 −0.111 0.323 −0.263 0.008 −0.266 0.008 −0.107 0.295
Changed levels
Free fatty acids 0.275 <0.001 0.275 <0.001 0.247 0.001 0.231 0.035 0.226 0.040 0.292 0.008 0.304 0.002 0.301 0.002 0.190 0.060
Triglycerides 0.022 0.767 0.019 0.800 −0.084 0.257 −0.166 0.131 −0.195 0.077 −0.299 0.006 0.207 0.038 0.221 0.028 0.151 0.138
HDL cholesterol 0.366 <0.001 0.365 <0.001 0.354 <0.001 0.411 <0.001 0.405 <0.001 0.412 <0.001 0.313 0.002 0.310 0.002 0.266 0.008
∮Log-transformed.
Tested by Partial correlation analysis.
r1: correlation coefficient after adjusting for age, sex, and changes in body weight.
r2: correlation coefficient after adjusting for age, sex, changes in body weight and initial triglyceride levels.















Table 4 Multiple regressions to assess independent relationships between apolipoprotein A-V and clinical variables
Variable
Changed apo A-V levels







[95% CI†] [95% CI†] [95% CI†]
APOA5 -1131
T > C genotype
−24.532 [−47.596, −1.469] 0.037 - - - -
Age 0.427 [−0.839, 1.693] 0.507 0.477 [−1.512, 2.465] 0.634 −0.204 [−1.880, 1.471] 0.809
Baseline levels
Body mass index 1.078 [−3.811, 5.966] 0.664 0.812 [−6.501, 8.124] 0.826 2.696 [−4.004, 9.396] 0.426
Apo A-V∮ −107.870 [−132.432, −83.308] <0.001 −112.767 [−151.730, −73.804] <0.001 −101.958 [−133.939, −69.976] <0.001
Triglycerides∮ −17.959 [−43.321, 7.402] 0.164 −19.362 [−61.602, 22.877] 0.364 −14.284 [−48.109, 19.542] 0.404
HDL cholesterol∮ 24.125 [−31.326, 79.576] 0.392 −2.779 [−88.093, 82.536] 0.948 49.796 [−27.506, 127.097] 0.204
Glucose∮ −33.234 [−182.983, 116.516] 0.662 −210.610 [−463.912, 42.691] 0.102 129.957 [−64.812, 324.727] 0.188
HOMA-IR∮ 22.975 [−12.858, 58.809] 0.207 12.221 [−49.304, 73.746] 0.693 14.817 [−30.146, 59.781] 0.514
Free fatty acids∮ 26.503 [−4.251, 57.257] 0.551 42.963 [−5.154, 91.081] 0.079 9.158 [−32.164, 50.480] 0.661
Changed levels
Triglycerides∮ 0.066 [−0.152, 0.284] 0.551 −0.404 [−0.784, −0.024] 0.038 0.349 [0.085, 0.612] 0.010
HDL cholesterol∮ 2.550 [1.455, 3.645] <0.001 3.280 [1.274, 5.287] 0.002 2.239 [0.915, 3.563] 0.001
Glucose∮ −0.121 [−1.018, 0.775] 0.790 −0.631 [−2.905, 1.643] 0.582 −0.363 [−1.397, 0.671] 0.487
HOMA-IR∮ −4.036 [−17.793, 9.721] 0.563 0.119 [−22.914, 23.152] 0.992 −8.468 [−25.418, 8.481] 0.324
Free fatty acids∮ 0.085 [0.034, 0.135] 0.001 0.079 [−0.005, 0.164] 0.065 0.071 [0.006, 0.137] 0.034
R2 = 0.459, adjusted R2 = 0.416 R2 = 0.524, adjusted R2 = 0.440 R2 = 0.525, adjusted R2 = 0.455
P < 0.001 P < 0.001 P < 0.001
∮Log-transformed. †Confidence interval.
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ation is consistent with our finding that TT allele carriers
who consumed whole grains and legumes had a significant
decrease in fasting triglyceride levels. In contrast, C allele
carriers had an increase in fasting triglyceride levels des-
pite adhering to the same diet. This observation suggests
that the magnitude of the effect of the APOA5 gene on
triglyceride levels is masked when metabolic conditions
improved as a consequence of the whole grain and legume
diet. This result is consistent with previous reports that
lifestyle modification attenuates the biological effect of a
genetic predisposition on metabolic profiles and diabetes
risk [32].
Exercise has also been shown to increase insulin sensi-
tivity in patients with type 2 diabetes [33]. Another study
showed that exercise increased insulin sensitivity in both
type 2 diabetes and healthy control subjects with the same
age, BMI, and initial triglyceride levels. However, although
exercise had little effect on triglyceride levels in control
subjects, exercise significantly decreased triglyceride levels
in patients with type 2 diabetes. Therefore, exercise may
be therapeutic for abnormal lipid metabolism [34]. This
result suggests that if exercise is therapeutic only for
abnormal lipid metabolism, then an innate humangenome sequence for this effect may not exist. Previous re-
search has suggested that the promoter variant -1131 T >C
is in strong linkage disequilibrium with APOA5 -3A >G,
which occurs in the ‘Kozak’ sequence in APOA5, and
disruption of this sequence has been shown in other genes
to severely disrupt ribosomal translation efficiency, leading
to lower levels of apo A-V from this mRNA. Therefore, the
C allele may itself not be functional, but is acting as a
marker for the -3A >G that may contribute to lower apo
A-V levels [35]. More studies are needed to determine
whether diet and exercise can improve apo A-V levels
in individuals with the C allele.
Apo A-V would increase the binding of TG-rich
lipoproteins to glycosaminoglycans present on the sur-
face of endothelial cells, thus rendering these lipoproteins
more accessible to LPL [36]. Therefore, decreased apo
A-V levels may reduce LPL-mediated TG hydrolysis
of chylomicrons and VLDL and delay the clearance of
lipoprotein remnants by the liver [37]. After hydroly-
sis of TG-rich lipoproteins by LPL, surface compo-
nents are detached to form native HDL of discoidal
form [38]. Thus, the delayed TG hydrolysis, attributable to
apo A-V deficiency, reduces the availability of surface
components of triglyceride-rich lipoproteins, thereby
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In this way, apo A-V is associated with HDL forma-
tion, and this may result in significant contribution
of HDL as independent predictors for changes in apo
A-V levels.
There are several limitations in our study. First, dietary
intake during the 3-year dietary intervention was based
on self-reports obtained from weighed food. However,
measurement errors from self-reported dietary intake
and lifestyle variables are relatively small [39]. Second,
the euglycemic glucose clamp technique and 2-hour
glucose tolerance test were not performed. Finally, we
focused on individuals with IFG or new-onset type 2
diabetes; therefore, our results cannot be generalized to
the greater population. Despite these limitations, we
found that the APOA5 -1131 T > C polymorphism plays
an important role in the metabolic response to a 3-year
dietary intervention in patients with IFG or new-onset
type 2 diabetes. Whole-grain ingestion prevented the
age-related increase in triglyceride levels in patients with
IFG or new-onset type 2 diabetes who carried the TT
allele but not the C allele of the APOA5 -1131 T > C
polymorphism. Our results suggest that the C allele
contributes to the increased triglyceride levels among
the Korean population. In addition, a positive rela-
tionship between triglyceride levels and the C allele
may affect the onset of diabetes. However, long-term
case–control studies and studies of the underlying
mechanisms are needed to determine the relationship
between the APOA5 -1131 T > C polymorphism and
human health.Conclusions
This study showed that the dietary intervention prevented
an age-related increase in triglyceride levels in individuals
with IFG or new-onset type 2 diabetes who possess
the TT allele, but not the CT or CC allele, of the
APOA5 -1131 T > C polymorphism.
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